Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …

Immune checkpoint blockade has revolutionized the field of oncology, inducing durable anti-
tumour immunity in solid tumours. In patients with advanced prostate cancer …

Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …

Developing strategies to inflame tumors is critical for increasing response to immunotherapy.
Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell …

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional, and …

Metastatic castration-resistant prostate cancer (mCRPC) is immunologically" cold" and
predominantly resistant to immune checkpoint therapy due to few tumor-infiltrating T cells …

Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …

Metastatic prostate cancer (mPC) comprises a spectrum of diverse phenotypes. However,
the extent of inter-and intra-tumor heterogeneity is not established. Here we use digital …

Abstract B7 homolog 3 (B7-H3; CD276), a tumor-associated antigen and possible immune
checkpoint, is highly expressed in prostate cancer (PCa) and is associated with early …